title: Serum antithrombin III and alpha-2-antiplasmin concentrations in patients with Hodgkin's disease in the course of chemotherapy.
abstract: Disturbances in hemostasis in cancer disease frequently occur. This clinical situation may contribute to the spread and metastasis of cancer. The determination of inhibitors controlling hemostasis especially during treatment may be of value for the evaluation of effectiveness of treatment and balancing of hemostasis. Twenty four patients diagnosed with Hodgkin's disease were introduced to our studies. The level of antithrombin III (AT-III) and alpha-2-antiplasmin (alpha-2-AP) in sera were determined before, during and after treatment with MOPP. We found decrease of AT-III concentration before treatment, and chemotherapy increased the level of this inhibitor but still below the level of control. Alpha-2-AP concentration was higher in patients and MOPP application decreased the level below the values found in controls. The determination of concentration of both inhibitors may be important for the evaluation of the effect of treatment in understanding how the disturbances of hemostasis may be equilibrated.
authors.affiliation: Department of Laboratory Clinical Diagnostics, Bialystok, Poland.
authors.forename: M
authors.initials: M
authors.lastname: Dabrowska
authors.forename: H
authors.initials: H
authors.lastname: Kemona
authors.forename: J
authors.initials: J
authors.lastname: Prokopowicz
authors.forename: J
authors.initials: J
authors.lastname: Kretowska
authors.forename: S
authors.initials: S
authors.lastname: Kiluk
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000990:Antithrombin III / Q000378:metabolism*; D005260:Female; D005341:Fibrinolysin / Q000378:metabolism*; D006689:Hodgkin Disease / Q000097:blood* / Q000188:drug therapy; D006706:Homeostasis / Q000187:drug effects; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000009:adverse effects; D008875:Middle Aged; D011241:Prednisone / Q000009:adverse effects; D011344:Procarbazine / Q000009:adverse effects; D014750:Vincristine / Q000009:adverse effects; D000511:alpha-Macroglobulins / Q000378:metabolism*
chemical_list: D000511:alpha-Macroglobulins; C024668:plasmin-alpha(2)-macroglobulin complex; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D000990:Antithrombin III; D005341:Fibrinolysin; D011241:Prednisone